A medicated chewing gum prototype that combats motion sickness could give a platform to incorporate other active ingredients with objectionable tastes into gum.
Arkema has restructured its business as part of its bid to generate €8bn ($10.3bn) in 2015 and become a world leader in the specialty chemicals sector.
Lundbeck has decided to stop making a cancer drug deeming the cost of securing API supplies too big and the likelihood to regulatory acceptance too small.
Siegfried says lower raw materials costs helped its API business grow in the first half of 2012 and set out plans to expand manufacturing operations in China.
The EC plan to extend drug GMP guidelines to APIs has met with a mixed response from industry groups, drugmakers and API manufacturers with some - like DSM and CEFIC – asking for clarification on the future of EudraLex Volume 4 Part II.
Hospira has bought Orchid Chemicals and Pharmaceutical’s active pharmaceutical ingredient (API) facility in Aurangabad, India, to support its expanding antibiotic business.
Higher revenue from recombinant albumin hyaluronic acid helped Novozymes’ biopharmaceutical business in the first half of 2012, but the firm expects growth to slow in the second half of the year.
GSK tells in-Pharmatechnologist.com that decision to close Indian API plant was prompted by rising cost of manufacture and availability of third party contractors.
The International Pharmaceutical Excipients Council (IPEC) Americas has welcomed new SFDA excipient quality and supervision regulations, which it says are largely consistent with its own guidelines.
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) wants members to suggest changes to tax laws governing pharmaceutical exports ahead of India’s next budget.
DSM will conduct further cost cutting at its Pharma business as part of a wider ‘profit improvement initiative’ that will see it cut 1,000 jobs over the next 18 months.
The Chinese Food and Drug Administration (SFDA) has confirmed that drugmakers and suppliers will take on more responsibility for ensuring excipient quality under new provisions.
Dr. Reddy’s may not have as big a hill to climb as some observers suggest to regain customers lost as a result of the closure of its Mexican API plant, according to Barclays.
Lonza has brought in a new exec to oversee cost reduction and efficiency efforts at its largest custom API manufacturing plant in what CEO Richard Ridinger calls the Visp challenge.
Granules India saw API sales rocket in the fiscal first quarter due – according to the firm – to an efficiency drive and the impact of rising prices in China.
Aegis Therapeutics has been granted a US patent for a novel formulation method and excipient that it claims reduces the risk of oxidative damage during MAb production and storage.
Novasep has joined the growing number of manufacturers betting on the antibody drug conjugate (ADC) market with a €3m investment at its plant in Le Mans, France.
More support for IPEC Americas’ proposed excipient safety review process emerged last week with Colorcon saying it makes Pharmas more likely to use new excipients.
